Dr Reddy’s launches cancer drug generic in US

Spread the love

News Our Bureau Hyderabad | Updated on June 19, 2020 Published on June 19, 2020 Pharma major Dr Reddy’s Laboratories Ltd has launched abiraterone acetate tablets, a therapeutic equivalent generic version of Zytiga, in the US market. The drug has been approved by the US Food and Drug Administration (USFDA).Zytiga is a trademark of Johnson…

At a glance:

Spread the love

News



Our Bureau


Hyderabad |
Updated on


June 19, 2020

Published on


June 19, 2020

Pharma major Dr Reddy’s Laboratories Ltd has launched abiraterone acetate tablets, a therapeutic equivalent generic version of Zytiga, in the US market.

The drug has been approved by the US Food and Drug Administration (USFDA).

Zytiga is a trademark of Johnson & Johnson Corporation. The Zytiga brand and generic market had US sales of approximately $454 million for the 12 months ended March 2020, according to IQVIA Health.

Hyderabad-based Dr Reddy’s abiraterone acetate is available in 250 mg tablets in bottle count sizes of 120, according to a release.

Abiraterone acetate tablets are a CYP17 inhibitor indicated in combination with rednisone for the treatment of patients with metastatic castration-resistant prostate cancer.

Published on


June 19, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism

Entrepreneur Podcast

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.